Skin Research Institute | Clinical Research Site

Research site

(Unclaimed)

Location

4425 Ponce de Leon Boulevard, Suite 200, Coral Gables, Florida, United States of America

Site insights

Top conditions

Top treatments

AGN-151586

MT10109L

OnabotulinumtoxinA

PF-04965842

LIPO-202

AVP-786

Sofpironium Bromide

AIV001

BOTOX

AXS-07

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 39 total trials

A Study to Assess Safety and Effectiveness of Injections of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Change of Mid-Face Volume

Facial fullness is often regarded as a characteristic feature of a youthful face. Chronic reduction of collagen, elastin, and glycosaminoglycans cont...

Enrolling

Mid Face Volume Deficit

Device: VOLUMA XC

Device: NOA VOLUME

A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony)

A study to evaluate overall participant satisfaction of face and neck appearance after treatment with onabotulinumtoxinA, JUVÉDERM® products, KYBELLA...

Enrolling

Facial Contouring

Drug: KYBELLA

Device: CoolSculpting Elite System

A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance

The purpose of this study is to evaluate the safety and effectiveness of JUVÉDERM products in adults seeking improvement in facial volume and/or skin...

Enrolling

Mid Face Volume Deficit

Device: JUVÉDERM VOLUMA XC

Device: JUVÉDERM VOLUX XC

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA)

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Enrolling

Alopecia Areata

Drug: Placebo

Drug: Upadacitinib

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting

Dermatitis, Atopic

Drug: Abrocitinib 200 mg

Drug: Abrocitinib 100 mg